COLL Collegium Pharmaceutical Quarterly EPS earnings growth

Official company branding of Collegium Corp (COLL)

How does production outsourcing via CMO partners affect the stability of Collegium Pharmaceutical (COLL)? The answer lies in the hiring of rigorous regulatory experts and high employee motivation. Tracking quarterly EPS growth confirms the business's resilience, as demand for analgesics is independent of GDP. The value of -28.70 reflects the metric's baseline, capturing the issuer's financial health.

Collegium Pharmaceutical, Inc. (COLL) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/14/2026

Financial and market metric breakdowns for Collegium Pharmaceutical (COLL)

- market value and analyst target forecast:
Price Chart Collegium Corp|COLL - Consensus Target
- market capitalization data:
Market Capitalization Collegium Pharmaceutical, Inc.|COLL - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Collegium Pharmaceutical|COLL - Total Stockholders' Equity|Market Value to Book Value Ratio collegiumpharma.com|COLL - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Collegium Pharmaceutical|COLL - Long-Term Debt to Equity|Short-Term Debt to Capital Collegium Corp|COLL - Company Cumulative Debt|Debts to Book Capitalization Collegium Pharmaceutical|COLL - Long-Term Indebtedness|Company Short-Term Debts Collegium Pharmaceutical|Quick Liquidity Indicator collegiumpharma.com
- earnings and market multiples details:
COLL - Net Profit|Expected Profit Collegium Pharmaceutical|COLL - Price to Earnings Ratio|Projected Price to Earnings Collegium Pharmaceutical|COLL - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Collegium Corp|COLL - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Collegium Pharmaceutical|COLL - Earnings per share for the trailing year|Quarterly EPS earnings growth collegiumpharma.com|COLL - Earnings growth in current year|Net earnings per share growth forecast for next year Collegium Pharmaceutical
- sales volume and revenue indicators:
COLL - Company Sales Revenue|Company Projected Revenue Collegium Corp|COLL - Market Cap to Revenue|Forward P/S Multiple Collegium Corp
Comprehensive company analysis:Collegium Pharma - COLL
Manufactured product of Collegium Corp

To minimize capital risks, it is necessary to assess the resilience of net income to cost inflation. This metric measures the growth of EPS relative to personnel expenses, determining the real trend in margins. By analyzing the growth rate of quarterly earnings per share, an investor identifies revenue vulnerabilities in real time. For Collegium Pharmaceutical (COLL), this confirms the effectiveness of scaling niche drugs. A unified sales force combined with low outsource manufacturing costs maximizes operating profitability.

Competitors of Collegium Pharmaceutical

Indivior Corp (INDV) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months Cronos|CGC (Canopy Growth Corp.) - Quarterly EPS earnings growth|HITI: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Aurora Cannabis, Inc. (ACB)|Year-over-year net earnings per share growth for the last 12 months Achieve Life Sciences, Inc. ACHV|skyebioscience.com - Year-over-year net earnings per share growth for the last 12 months|Anebulo (ANEB) - Earnings per share growth in annualized terms for the last twelve months|Canndoc - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months NTRB (nutriband.com)|Nasus Pharma Ltd (NSRX) - Year-over-year earnings per share growth for the last twelve months|India Globalization Capital - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months MIRA Pharma|FLGC: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months IMC (IMCC)|ADIL: Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth ARTL (Artelo)|Year-over-year earnings per one share growth for the last 12 months ENSC|Titan Pharmaceuticals - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Greenlane Holdings|inmedpharma.com (INM) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months AKAN|Year-over-year earnings per share growth for the last twelve months Enveric Corp|Earnings per share growth in annualized terms for the last twelve months brightgreen.us BGXX|Year-over-year net earnings per share growth for the last 12 months HPCO (Hempacco Co Inc.)